For the last year, any discussion of the obesity-drug market has come with an asterisk: Everything will change once pill versions of the popular GLP-1 drugs arrive. Those potentially cheaper alternative to injectables could mean a larger slice of the millions of Americans with obesity will try out the medicine.

On Tuesday, congressional leaders spent two hours taking to task Novo Nordisk Chief Executive Officer Lars Fruergaard Jørgensen over the high price of the company’s diabetes and obesity drugs, Ozempic and Wegovy. Now the question is whether those prices will change.

The bankruptcy of Steward Health has become the latest cautionary tale about private equity’s involvement in health care. Cerberus Capital Management’s purchase in 2010 of several Massachusetts-based nonprofit hospitals was meant to be a life preserver for the struggling chain, but instead its woes deepened, compromising patient care.

Merck & Co. has said nothing publicly about rumors that it is in talks to buy Seagen, a biotech company working on cancer treatments, for about $40 billion.